Compare MQT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MQT | LUNG |
|---|---|---|
| Founded | 1992 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.3M | 63.6M |
| IPO Year | N/A | 2020 |
| Metric | MQT | LUNG |
|---|---|---|
| Price | $10.02 | $2.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 52.5K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $91,664,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $8.59 | $1.31 |
| 52 Week High | $10.67 | $9.37 |
| Indicator | MQT | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 71.32 |
| Support Level | $9.88 | $1.96 |
| Resistance Level | $10.08 | $1.74 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 60.00 | 91.13 |
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a diversified, closed-end investment management company. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S federal income taxes. The majority of its managed assets are invested in municipal bonds exempt from U.S. federal income taxes. The fund invests in municipal bonds that are in the three highest quality rating categories, or are deemed to be of comparable quality by the investment adviser at the time of investment. These are mainly long-term municipal bonds with maturities of more than ten years at the time of investment, having exposure to different sectors. The fund can also invest directly in such securities or synthetically through the use of derivatives.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.